Acetylsalicylic acid as an adjuvant therapy for schizophrenia
<p>Abstract</p> <p>Background</p> <p>Findings from both epidemiological and basic research point to the possibility that NSAIDS impede the deterioration in schizophrenia.</p> <p>Methods</p> <p>To study the efficacy of acetylsalicylic acid we will...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2006-10-01
|
| Series: | Trials |
| Online Access: | http://www.trialsjournal.com/content/7/1/31 |
| _version_ | 1811312395546525696 |
|---|---|
| author | Grobbee Diederick E Heijnen Cobi J Huisman Anne-Margriet Kahn René S Selten Jean-Paul Laan Wijnand Burger Huibert |
| author_facet | Grobbee Diederick E Heijnen Cobi J Huisman Anne-Margriet Kahn René S Selten Jean-Paul Laan Wijnand Burger Huibert |
| author_sort | Grobbee Diederick E |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Findings from both epidemiological and basic research point to the possibility that NSAIDS impede the deterioration in schizophrenia.</p> <p>Methods</p> <p>To study the efficacy of acetylsalicylic acid we will perform a randomized placebo controlled double-blind add-on trial of 80 inpatients and outpatients with schizophrenia, schizophreniform or schizoaffective disorder. Patients will be 1:1 randomized to either 3 months 1000 mg acetylsalicylic acid per day or 3 months placebo, in addition to their regular antipsychotic treatment. All patients will receive pantoprazole treatment for gastroprotection. The outcomes of this study are 3-month change in psychotic and negative symptom severity, cognitive function, and several immunological parameters.</p> <p>This trial may (1) yield a new (adjuvant) therapy for schizophrenia and (2) add to the knowledge on the pathogenesis of this major psychiatric disorder.</p> |
| first_indexed | 2024-04-13T10:35:30Z |
| format | Article |
| id | doaj.art-fcf0da54b4774371b5f16cb1abe984c5 |
| institution | Directory Open Access Journal |
| issn | 1745-6215 |
| language | English |
| last_indexed | 2024-04-13T10:35:30Z |
| publishDate | 2006-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Trials |
| spelling | doaj.art-fcf0da54b4774371b5f16cb1abe984c52022-12-22T02:50:04ZengBMCTrials1745-62152006-10-01713110.1186/1745-6215-7-31Acetylsalicylic acid as an adjuvant therapy for schizophreniaGrobbee Diederick EHeijnen Cobi JHuisman Anne-MargrietKahn René SSelten Jean-PaulLaan WijnandBurger Huibert<p>Abstract</p> <p>Background</p> <p>Findings from both epidemiological and basic research point to the possibility that NSAIDS impede the deterioration in schizophrenia.</p> <p>Methods</p> <p>To study the efficacy of acetylsalicylic acid we will perform a randomized placebo controlled double-blind add-on trial of 80 inpatients and outpatients with schizophrenia, schizophreniform or schizoaffective disorder. Patients will be 1:1 randomized to either 3 months 1000 mg acetylsalicylic acid per day or 3 months placebo, in addition to their regular antipsychotic treatment. All patients will receive pantoprazole treatment for gastroprotection. The outcomes of this study are 3-month change in psychotic and negative symptom severity, cognitive function, and several immunological parameters.</p> <p>This trial may (1) yield a new (adjuvant) therapy for schizophrenia and (2) add to the knowledge on the pathogenesis of this major psychiatric disorder.</p>http://www.trialsjournal.com/content/7/1/31 |
| spellingShingle | Grobbee Diederick E Heijnen Cobi J Huisman Anne-Margriet Kahn René S Selten Jean-Paul Laan Wijnand Burger Huibert Acetylsalicylic acid as an adjuvant therapy for schizophrenia Trials |
| title | Acetylsalicylic acid as an adjuvant therapy for schizophrenia |
| title_full | Acetylsalicylic acid as an adjuvant therapy for schizophrenia |
| title_fullStr | Acetylsalicylic acid as an adjuvant therapy for schizophrenia |
| title_full_unstemmed | Acetylsalicylic acid as an adjuvant therapy for schizophrenia |
| title_short | Acetylsalicylic acid as an adjuvant therapy for schizophrenia |
| title_sort | acetylsalicylic acid as an adjuvant therapy for schizophrenia |
| url | http://www.trialsjournal.com/content/7/1/31 |
| work_keys_str_mv | AT grobbeediedericke acetylsalicylicacidasanadjuvanttherapyforschizophrenia AT heijnencobij acetylsalicylicacidasanadjuvanttherapyforschizophrenia AT huismanannemargriet acetylsalicylicacidasanadjuvanttherapyforschizophrenia AT kahnrenes acetylsalicylicacidasanadjuvanttherapyforschizophrenia AT seltenjeanpaul acetylsalicylicacidasanadjuvanttherapyforschizophrenia AT laanwijnand acetylsalicylicacidasanadjuvanttherapyforschizophrenia AT burgerhuibert acetylsalicylicacidasanadjuvanttherapyforschizophrenia |